A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
Thermodynamically Stable Ionic Liquid Microemulsions Pioneer Pathways for Topical Delivery and Peptide Application. Bioactive Materials, vol
Early Phase 2 data suggest substantial weight loss, though it is important to note that no direct head-to-head trials comparing retatrutide with tirzepatide or other agents have been conducted
1 Introduction Besides the traditional standard-of-care agents, newer classes of glucose-lowering agents have been introduced and changed the landscape of type 2 diabetes mellitus (T2DM) management ( The CV benefits were variable among the different available GLP-1 RAs
Existing GLP1R agonists come with boxed warnings of thyroid cancer and pancreatitis, based mainly on rodent studies, where the effects of GLP1R agonism have noted species differences (For example, weight loss in rodents is mainly due to increased energy expenditure, whereas in humans it occurs via less food intake [54] )
Participants reporting liver-related adverse events, which were mostly non-serious, were higher in the semaglutide 2.4 mg group (7.5%) than with placebo (1.5%)
.png)
